Obesity Linked To Increased Risk For Dementia
Obesity may increase adults' risk for having dementia, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their analysis of published obesity and dementia prospective follow-up studies over the past two decades shows a consistent relationship between the two diseases. The results are published by The International Association for the Study of Obesity in the May, 2008 issue of Obesity Reviews.
Molecules In Plants May Have Beneficial Effect On Alzheimer's Disease
A set of molecules found in certain plants appears to have a beneficial effect in brain tissue associated with Alzheimer's disease, according to a new study conducted in mice. The study was led by researchers at the University of South Florida and Cedars-Sinai Medical Center. An article in the Journal of Cellular and Molecular Medicine is available online.Terrence Town, Ph.D., one of the senior authors of the study, is available to provide more information about this study.
Promoting Dignity And Independence For People Who Suffer From Dementia
Two projects by South Essex Partnership NHS Foundation Trust (SEPT) to promote dignity and independence for people who suffer from dementia were highly commended at this year's East of England Health and Social Care Awards. The innovative projects 'Lasting Memories' and 'My life Story' were launched in December 2007 and work closely with patients, their carers, families and friends to improve their quality of life.
Court Of Appeal Makes Decision Following Ruling That Nice Process On Anti-Dementia Medicines Unfair, UK
Eisai Limited, the licence holder of Aricept (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that the Court of Appeal has released its decision on the consequential issues arising from Court of Appeal's recent ruling that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer's disease was procedurally unfair.
Obesity Significantly Raises Dementia Risk - Underweight Also Raises Risk
Being obese can increase the risk of Alzheimer's Disease by as much as 80 percent, according to a study in the May issue of Obesity Reviews.But it's not just weight gain that poses a risk. People who are underweight also havean elevated risk of dementia, unlike people who are normal weight or overweight.
Patent Claims Allowed Covering Samaritan's Alzheimer's Memory Recovery Drug In Australia
Samaritan Pharmaceuticals (OTCBB:SPHC), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office. The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills.
Alzheimer's Disease: Modulating Enkephalin May Reduce Cognitive Deficits
Alzheimer's disease (AD) is an incurable disease that is increasing in prevalence and will increase even more rapidly as the Baby Boom generation enters the age of highest risk. The available AD drugs are only partially effective in some patients. New strategies are urgently needed.
Study Outlines Misconceptions About Alzheimers, Australia
Better targeted education is needed to prevent misconceptions held by the general public about Alzheimer's disease, according to Queensland University of Technology researcher Dr Karen Sullivan. Registered psychologist and senior lecturer for the School of Psychology and Counselling in the Faculty of Health, Dr Sullivan has been studying people's misconceptions about the condition for the past five years, and said there were a number of things which people misunderstood about it.
EPIX Pharmaceuticals Initiates Phase 2b Program In Alzheimer's Disease
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has begun its Phase 2b program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil (Aricept ).
Study Identifies New Gene For Late-Onset Alzheimer's Disease - Findings Lead To New Line Of Investigation Into Alzheimer's Research
A new study has identified the cause of late-onset Alzheimer's disease in several large families in which many siblings suffer from the disease. The gene, known as TRPC4AP on chromosome 20, is involved with calcium regulation. It is known that when calcium levels are not carefully controlled, cells can die, leading to the onset of disease. Alzheimer's disease is a complex progressive neurodegenerative disorder in which patients suffer from profound cognitive decline.